Shuttle Current Deferred Revenue from 2010 to 2025
| SHPH Stock | USD 0.39 0.01 2.50% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 435.3 K | Current Value 333.8 K | Quarterly Volatility 75.4 K |
Check Shuttle Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Shuttle Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 9.1 M, Tax Provision of 0.0 or Depreciation And Amortization of 5.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.002 or PTB Ratio of 0.0033. Shuttle financial statements analysis is a perfect complement when working with Shuttle Pharmaceuticals Valuation or Volatility modules.
Shuttle | Current Deferred Revenue |
Latest Shuttle Pharmaceuticals' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Shuttle Pharmaceuticals over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Shuttle Pharmaceuticals' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Shuttle Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Shuttle Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 276,070 | |
| Geometric Mean | 267,692 | |
| Coefficient Of Variation | 27.30 | |
| Mean Deviation | 65,561 | |
| Median | 228,389 | |
| Standard Deviation | 75,376 | |
| Sample Variance | 5.7B | |
| Range | 207K | |
| R-Value | 0.77 | |
| Mean Square Error | 2.4B | |
| R-Squared | 0.60 | |
| Significance | 0.0004 | |
| Slope | 12,245 | |
| Total Sum of Squares | 85.2B |
Shuttle Current Deferred Revenue History
About Shuttle Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Shuttle Pharmaceuticals' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Shuttle Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 435.3 K | 333.8 K |
Currently Active Assets on Macroaxis
When determining whether Shuttle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Shuttle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Shuttle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Shuttle Pharmaceuticals Stock:Check out the analysis of Shuttle Pharmaceuticals Correlation against competitors. For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.